NJ Appeals Court Opens Door for Medical Marijuana Users to Sue Employers

Appellate Division Reverses Trial Court

The three-judge panel found that New Jersey's medical marijuana statute doesn't limit discrimination claims to existing employees. The Appellate Division reversed a trial court dismissal, holding that the Compassionate Use Medical Marijuana Act's anti-discrimination provision applies to applicants who've received conditional job offers. This marks the first time a New Jersey appellate court has addressed whether pre-employment rescissions based on medical cannabis use constitute actionable discrimination.

The trial court had granted summary judgment to the employer, reasoning that the statute's protections extended only to individuals already employed at the time of adverse action. The appellate panel rejected that reading. It found no textual basis in the statute to exclude job applicants from the law's scope.

Case Background and Procedural History

The plaintiff, a registered medical marijuana patient, alleged the employer withdrew a job offer after a pre-employment drug screen detected THC. According to court filings, the plaintiff had disclosed his medical cannabis registration during the hiring process and provided documentation from his physician. The employer rescinded the conditional offer citing company drug policy, prompting the plaintiff to file a discrimination claim under the Compassionate Use Medical Marijuana Act.

The trial court dismissed the complaint in 2025, holding that the statute's text didn't clearly extend to applicants. On appeal, the plaintiff argued that the law's plain language prohibits discrimination against any individual based on status as a registered qualifying patient.

Statutory Interpretation and Plain Language

The appellate court applied canons of statutory construction, finding that the Act's anti-discrimination clause contains no employee-only limitation. The panel analyzed the text of the Compassionate Use Medical Marijuana Act, which prohibits penalizing any person solely for lawful medical marijuana use. The court noted that the legislature used broad language—"any person"—rather than restricting protections to "employees" or "workers."

Established New Jersey precedent requires courts to give effect to the legislature's chosen words, the decision noted. Imposing an employee-only limitation would require reading language into the statute that the legislature didn't include, the panel found. The court also examined the Act's remedial purpose, concluding that a narrow construction would undermine the legislature's intent to protect medical marijuana patients from employment discrimination.

Implications for Employer Drug Policies

The ruling exposes New Jersey employers to discrimination claims when they rescind job offers based on lawful off-duty medical cannabis use. Employers who maintain zero-tolerance drug policies now face potential liability if they withdraw conditional offers after positive THC screenings, even for safety-sensitive positions. That said, the decision doesn't address whether employers can still enforce workplace impairment policies or prohibit on-duty use.

Employment attorneys expect a wave of litigation from applicants who lost job offers after disclosing medical marijuana use or testing positive for THC. Employers may need to revise pre-employment screening protocols and rescission procedures to comply with the expanded interpretation of the Compassionate Use Medical Marijuana Act.

Safety-Sensitive Positions Remain Unresolved

The appellate decision didn't address whether the statute permits employers to exclude medical marijuana users from safety-sensitive roles. The court noted that the case involved a non-safety-sensitive position and declined to opine on whether different standards apply to jobs implicating public safety or federal regulations. That question remains open.

New Jersey's medical marijuana statute includes a provision stating that employers need not accommodate on-site use or permit employees to work while impaired. But the statute doesn't explicitly carve out safety-sensitive positions, leaving employers uncertain about the scope of permissible exclusions. Federal contractors and employers subject to Department of Transportation drug-testing rules face additional complexity, as federal law still classifies marijuana as a Schedule I controlled substance.

Comparison to Other State Frameworks

New Jersey joins a growing number of states where courts have extended medical marijuana employment protections to job applicants. Similar rulings have emerged in Massachusetts, Rhode Island, and Connecticut, where courts interpreted state medical cannabis laws to prohibit pre-employment discrimination. Other jurisdictions, including Pennsylvania and Arizona, have reached opposite conclusions, holding that anti-discrimination provisions apply only to current employees.

The split in state court interpretations reflects broader uncertainty about the scope of medical marijuana employment protections nationwide. For context on how state frameworks vary, see the CannIntel topic hub on medical marijuana employment protections. The New Jersey decision aligns with the trend in plaintiff-friendly jurisdictions but deepens the interstate divergence on this issue.

Next Steps and Employer Response

The case returns to the trial court for further proceedings on the merits of the plaintiff's discrimination claim. The employer may petition the New Jersey Supreme Court for review or proceed to trial on the underlying facts. Legal observers expect the employer to seek Supreme Court review given the decision's broad implications for hiring practices statewide.

In the meantime, New Jersey employers should consult employment counsel before rescinding job offers based on medical marijuana use. Recommended steps include revising offer letters to clarify contingencies, training HR personnel on the Compassionate Use Medical Marijuana Act's requirements, and evaluating whether drug-testing protocols comply with the appellate court's interpretation. Employers in safety-sensitive industries should monitor further developments closely, as the unresolved question of permissible exclusions will likely reach the Supreme Court within the next year.